Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Inozyme Pharma, Inc. (INZY : NSDQ)
 
 • Company Description   
Inozyme Pharma Inc. is a biopharmaceutical company. It engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue and skeleton diseases. The company's product candidate consist INZ-701, which is in clinical stage. Inozyme Pharma Inc. is based in Boston, Massachusetts.

Number of Employees: 50

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.22 Daily Weekly Monthly
20 Day Moving Average: 304,050 shares
Shares Outstanding: 40.10 (millions)
Market Capitalization: $169.21 (millions)
Beta: 1.12
52 Week High: $19.58
52 Week Low: $3.54
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -14.23% -3.40%
12 Week -26.99% -19.74%
Year To Date -38.12% -24.93%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
321 SUMMER STREET SUITE 400
-
BOSTON,MA 02210
USA
ph: 857-330-4340
fax: -
ir@inozyme.com http://www.inozyme.com
 
 • General Corporate Information   
Officers
Axel Bolte - Chief Executive Officer; President and Director
Douglas Treco - Chairman
Stephen DiPalma - Interim Chief Financial Officer
Sarah Bhagat - Director
Reinaldo Diaz - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45790W108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 40.10
Most Recent Split Date: (:1)
Beta: 1.12
Market Capitalization: $169.21 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.49 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.33 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 22.59% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.80
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -51.06%
vs. Previous Quarter: 10.13%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -53.41
12/31/21 - -43.36
09/30/21 - -34.30
ROA
03/31/22 - -48.19
12/31/21 - -39.84
09/30/21 - -31.90
Current Ratio
03/31/22 - 8.20
12/31/21 - 9.92
09/30/21 - 14.60
Quick Ratio
03/31/22 - 8.20
12/31/21 - 9.92
09/30/21 - 14.60
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 2.35
12/31/21 - 4.62
09/30/21 - 5.32
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©